Supplemental Table 6. Pharmacokinetic analysis of pacritinib concentration over time

Day	Dosing	Variable	Units	N	Mean	SD	CV%	Median
D0	100 BID	AUClast	h*ng/mL	8	41774.9	13697.3	32.79	37398.1
		Cmax	ng/mL	8	2585.8	705.4	27.28	2413.2
		Tmax	h	8	22.5	4.2	18.86	24.00
D0	100 QD	AUClast	h*ng/mL	10	35347.7	12677.0	35.86	31803.9
		Cmax	ng/mL	10	1939.9	588.8	30.35	1717.4
		Tmax	h	10	10.4	8.0	77.35	8.00
D21	100 BID	AUClast	h*ng/mL	5	216821.2	117279.3	54.09	190665.0
		Cmax	ng/mL	5	9352.0	4931.5	52.73	8252.3
		Tmax	h	5	13.6	10.0	73.82	12.00
D21	100 QD	AUClast	h*ng/mL	4	147191.4	58248.2	39.57	155676.2
		Cmax	ng/mL	4	6603.8	2340.2	35.44	6860.1
		Tmax	h	4	6.0	4.0	66.67	4.00

Plasma samples were analyzed using HPLC/MS/MS (Quinta Analytica) for pacritinib content using a total of 111 plasma samples. Pharmacokinetic parameters of pacritinib were calculated and presented here in table format. AUClast is equal to AUC(0-24h). Analysis of variance demonstrated no significant effect of dosing regimen (100mg daily vs. twice daily) at 5% significance level for AUC(0-24h).